(Q43672297)

25 November 2017

0 references

1 reference

title

Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there (English)

1 reference

25 November 2017

main subject

liver transplantation

1 reference

1 reference

Samuel D

1

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Journal of Hepatology

1 reference

25 November 2017

volume

34

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

943-945

1 reference

Liver transplantation in European patients with the hepatitis B surface antigen

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900102-7

7 January 2021

10.1016/S0168-8278(01)00102-7

Identifiers

DOI

1 reference

25 November 2017

1 reference